CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02312622
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:25.544257+00:00
Published At: 2019-09-10T00:00:00+00:00
Record Updated At: 2023-12-12
Results Posted At: 2019-09-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage IV Non-small Cell Lung Cancer (NSCLC)", "Recurrent Non-small Cell Lung Cancer (NSCLC)", "Extensive-stage Small Cell Lung Cancer (SCLC)", "Recurrent Small Cell Lung Cancer (SCLC)", "Tumors Metastatic to Brain", "Metastatic Breast Cancer (mBC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-12"
protocolSection.identificationModule.nctId: "NCT02312622"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-09-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.